Ophthalmologist Sonal Tuli, MD, discusses the FDA’s recent approval of teprotumumab for thyroid eye disease and what this new drug adds to the treatment landscape for this condition.
With increasing application of AI to health care, there is often concern that AI will replace clinicians. However, there is opportunity to optimize this partnership to improve patient care.
Eric A. Dietrich, PharmD, BCPS, and Kyle Davis, PharmD, BCPS
Eric A. Dietrich, PharmD, BCPS, and Kyle Davis, PharmD, BCPS
Subclinical hypothyroidism is an elevation in thyroid-stimulating hormone concentrations, with free thyroxine and free triiodothyronine concentrations within the reference range, with or without signs or...
First, let me say that I agree completely with the authors’ comments on sleep hygiene and the importance of removing the television set from the bedroom. When parents say they will just turn it off, I point...
